-
Posted by
Two Blokes Jul 28 -
Filed in
Stock
-
3 views
Britain's Oxford Biomedica on Monday maintained its annual forecasts for revenue and profit after it said first-half sales are expected to jump around 40% as orders remain strong for the cell and gene therapy developer and manufacturer.
